SG11201908624SA - Aryl hydrocarbon receptor antagonists and uses thereof - Google Patents

Aryl hydrocarbon receptor antagonists and uses thereof

Info

Publication number
SG11201908624SA
SG11201908624SA SG11201908624SA SG11201908624SA SG 11201908624S A SG11201908624S A SG 11201908624SA SG 11201908624S A SG11201908624S A SG 11201908624SA SG 11201908624S A SG11201908624S A SG 11201908624SA
Authority
SG
Singapore
Prior art keywords
international
receptor antagonists
aryl hydrocarbon
hydrocarbon receptor
pct
Prior art date
Application number
Inventor
Arthur Glenn Romero
Kevin A Goncalves
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of SG11201908624SA publication Critical patent/SG11201908624SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIP0 I PCT °Ens °nolo mu DID Ho IIll IIII iflo oimIE (10) International Publication Number WO 2018/191476 Al (51) International Patent Classification: C07D 471/04 (2006.01) C12N 5/0789 (2010.01) CO7D 487/04 (2006.01) A61K 35/12 (2015.01) CO7D 519/00 (2006.01) (21) International Application Number: PCT/US2018/027265 (22) International Filing Date: 12 April 2018 (12.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/484,692 12 April 2017 (12.04.2017) US 62/613,382 03 January 2018 (03.01.2018) US 62/625,896 02 February 2018 (02.02.2018) US (71) Applicant: MAGENTA THERAPEUTICS, INC. [US/US]; 50 Hampshire Street, 8th Floor, Cambridge, Massachusetts 02139 (US). (72) Inventors: ROMERO, Arthur Glenn; 1201 Turn- berry Ridge Ct., Chesterfield, Missouri 63005 (US). GONCALVES, Kevin A.; 135 Clarendon Street, Apt. 14Z, Boston, Massachusetts 02116 (US). (74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = (54) Title: ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF do ti us AhR Atitalgtiltst Atthilty. -4— D 11.4S0 Cpd 5 Opci 16 Gotnttritt non M): (57) : The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopy- razines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expand- ed hemato poietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. N 00 O C [Continued on next page] WO 2018/191476 Al MIDEDIMOMMIDIREEMOMOHHOEHOMMEM# OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201908624S 2017-04-12 2018-04-12 Aryl hydrocarbon receptor antagonists and uses thereof SG11201908624SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484692P 2017-04-12 2017-04-12
US201862613382P 2018-01-03 2018-01-03
US201862625896P 2018-02-02 2018-02-02
PCT/US2018/027265 WO2018191476A1 (en) 2017-04-12 2018-04-12 Aryl hydrocarbon receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
SG11201908624SA true SG11201908624SA (en) 2019-10-30

Family

ID=62090081

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908624S SG11201908624SA (en) 2017-04-12 2018-04-12 Aryl hydrocarbon receptor antagonists and uses thereof

Country Status (15)

Country Link
US (4) US10457683B2 (en)
EP (1) EP3609890A1 (en)
JP (1) JP7352807B2 (en)
KR (1) KR20190138837A (en)
CN (1) CN110785419B (en)
AU (1) AU2018253115B2 (en)
BR (1) BR112019021282A2 (en)
CA (1) CA3057159A1 (en)
CO (1) CO2019012473A2 (en)
IL (2) IL293956A (en)
MX (1) MX2019011138A (en)
SG (1) SG11201908624SA (en)
TW (1) TW201841916A (en)
WO (1) WO2018191476A1 (en)
ZA (1) ZA201906209B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908624SA (en) 2017-04-12 2019-10-30 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and uses thereof
MX2019012431A (en) 2017-04-21 2020-08-03 Ikena Oncology Inc Indole ahr inhibitors and uses thereof.
KR20200051646A (en) 2017-08-17 2020-05-13 이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
EP3704232A1 (en) * 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019136159A1 (en) * 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2019156989A1 (en) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
EP3866797A1 (en) * 2018-10-17 2021-08-25 Magenta Therapeutics, Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
EP4065582A1 (en) 2019-11-26 2022-10-05 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
CN114369097B (en) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 Heteroaromatic AhR inhibitors
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US6080398A (en) 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
US5547892A (en) 1995-04-27 1996-08-20 Taiwan Semiconductor Manufacturing Company Process for forming stacked contacts and metal contacts on static random access memory having thin film transistors
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
NZ332174A (en) 1997-02-11 1999-03-29 Mallinckrodt Chemical Inc Reactor and method for solid peptide synthesis
ATE525477T1 (en) 1998-03-30 2011-10-15 Northwest Biotherapeutics Inc THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF CXCR-4 IN TUMORGENESIS
MXPA01009674A (en) 1999-03-24 2003-07-21 Anormed Inc Chemokine recpetor binding heterocyclic compounds.
AU2001265756A1 (en) 2000-04-27 2001-11-07 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
DE60103052T2 (en) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver USE OF CXCR4 ANTAGONISTS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
JP5414958B2 (en) 2000-06-05 2014-02-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Identification of human bone marrow-derived endothelial progenitor cells and use of human bone marrow-derived endothelial progenitor cells to improve the function of cardiomyocytes after ischemic injury
DE60236520D1 (en) 2001-08-16 2010-07-08 Univ Pennsylvania SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFEKTION AND / OR PRODRUG AND MEDICAMENT THERAPIES WITH SLOW RELEASE
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
ATE378336T1 (en) * 2002-09-19 2007-11-15 Schering Corp IMIDAZOPYRIDINES AS INHIBITORS OF CYCLIN DEPENDENT KINASES
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
JP2008509928A (en) 2004-08-13 2008-04-03 アノーメド インコーポレイテッド Chemokine combination to mobilize progenitor / stem cells
US20070033666A1 (en) 2005-06-24 2007-02-08 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
EP2484758B1 (en) 2005-10-18 2013-10-02 Precision Biosciences Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20070105864A1 (en) * 2005-11-10 2007-05-10 Schering Corporation Methods for inhibiting protein kinases
CN101421393B (en) 2006-02-14 2013-08-14 塞勒兰特治疗公司 Methods and compositions for enhancing engraftment of hematopoietic stem cells
AU2007259739B2 (en) 2006-06-14 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Agents for promoting the growth of hematopoietic stem cells
US8372797B2 (en) 2006-06-22 2013-02-12 Creative Medical Health, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1995316A1 (en) 2007-05-25 2008-11-26 Qiagen GmbH Method for gentle purification of cells, cell production and cell transfection
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
EP3098309B1 (en) 2007-10-31 2019-04-10 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
WO2010085699A2 (en) 2009-01-23 2010-07-29 The Johns Hopkins University Mammalian piggybac transposon and methods of use
EP2270025A1 (en) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Solid phase peptide synthesis of peptide alcohols
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011100505A2 (en) 2010-02-11 2011-08-18 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
WO2012083236A2 (en) * 2010-12-16 2012-06-21 Energia Technologies, Inc. Catalysts, methods of preparation of catalyst, methods of deoxygenation, and systems for fuel production
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821819A1 (en) * 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651944B1 (en) * 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2828239C (en) 2011-02-25 2020-10-06 Recombinetics, Inc. Genetically modified animals and methods for making the same
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
EP2694500B1 (en) * 2011-04-06 2015-05-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
WO2014080241A1 (en) * 2012-11-21 2014-05-30 Piramal Enterprises Limited Imidazopyridine compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9776979B2 (en) 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
BR112017021536A2 (en) 2015-04-06 2018-07-03 Harvard College compositions and methods for nonmyeloablative conditioning
CN108463463A (en) * 2016-01-14 2018-08-28 韩德株式会社 Compound, preparation method and its medical usage of antagonism A3 adenosine receptors
EP4049665A1 (en) 2016-03-15 2022-08-31 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
SG11201908624SA (en) 2017-04-12 2019-10-30 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and uses thereof
JP2021503008A (en) 2017-10-31 2021-02-04 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Compositions and Methods for Hematopoietic Stem Cell and Progenitor Cell Transplant Therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells

Also Published As

Publication number Publication date
BR112019021282A2 (en) 2020-05-19
JP7352807B2 (en) 2023-09-29
US20200123161A1 (en) 2020-04-23
IL269574A (en) 2019-11-28
US10919900B2 (en) 2021-02-16
CN110785419B (en) 2024-03-01
US10457683B2 (en) 2019-10-29
JP2020516639A (en) 2020-06-11
US20210179625A1 (en) 2021-06-17
US20190177330A1 (en) 2019-06-13
KR20190138837A (en) 2019-12-16
EP3609890A1 (en) 2020-02-19
CO2019012473A2 (en) 2020-02-18
US10351572B2 (en) 2019-07-16
TW201841916A (en) 2018-12-01
MX2019011138A (en) 2020-01-27
ZA201906209B (en) 2024-01-31
AU2018253115A1 (en) 2019-10-03
CA3057159A1 (en) 2018-10-18
AU2018253115B2 (en) 2022-08-11
US20180298013A1 (en) 2018-10-18
WO2018191476A1 (en) 2018-10-18
CN110785419A (en) 2020-02-11
IL293956A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
SG11201908624SA (en) Aryl hydrocarbon receptor antagonists and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909710XA (en) Indole ahr inhibitors and uses thereof
SG11201906883SA (en) Methods for the administration of certain vmat2 inhibitors
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201804038VA (en) Conditionally active heterodimeric polypeptides and methods of use thereof
SG11201805645QA (en) Lsd1 inhibitors
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201907023UA (en) Method of reducing neutropenia
SG11201807708SA (en) Estrogen receptor modulators
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof